research Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia
Dutasteride safely promotes hair growth and reduces hair loss, with mild side effects.
Search
for
Sort by
Research
780-810 / 1000+ results 
research Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research Effective treatment of alopecia universalis with oral tofacitinib: A case report
Oral tofacitinib successfully treated total body hair loss in one patient.
research Thyroid Hormone Receptor Agonist Promotes Hair Growth in Mice
TDM10842, a thyroid hormone receptor activator, was found to effectively promote hair growth in mice.
research Topical Application of Aprepitant Inhibits Erlotinib-induced Facial Dermatitis/Hair Loss
Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.
research ADVANCES IN PSORIASIS THERAPY
New psoriasis treatments are effective but come with side effects and risks.
research Logic-Based Modeling and Drug Repurposing for the Prediction of Novel Therapeutic Targets and Combination Regimens against E2F1-Driven Melanoma Progression
Cialis and Finasteride could be repurposed to treat aggressive melanoma.
research Enhanced ex vivo skin retention of bicalutamide using a nano-in-micro composite: Drug-loaded lipid vesicles in a dissolving microarray patch
The new drug delivery system improves bicalutamide skin retention for better treatment of hair loss.
research Smoothened receptor inhibitor vismodegib for the treatment of basal cell carcinoma: a retrospective analysis of efficacy and side effects
Vismodegib is effective for basal cell carcinoma but has severe side effects.
research Recent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases
New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.
research Prolonged remissions of metastatic breast cancer achieved with a six-drug regimen of relatively low toxicity
A six-drug treatment for metastatic breast cancer showed promising results with low side effects, especially in premenopausal women.
research Prostate cancer update: 2007
In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.
research Topical SCD-153, a 4-methyl itaconate prodrug, for the treatment of alopecia areata
SCD-153 shows promise as an effective topical treatment for alopecia areata.
research withdrawn
Dutasteride works better than finasteride for hair growth with similar side effects.
research Nanostructured lipid carriers promote percutaneous absorption and hair follicle targeting of tofacitinib for treating alopecia areata
Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.
research Flutamide
Flutamide helps with prostate cancer and some skin conditions but can harm the liver.
research Phase I-II trial of weekly bicalutamide in men with high PSA and negative biopsy
Weekly bicalutamide is safe and effective, with 50 mg/week recommended.
research JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
JAK inhibitors show promise for treating various skin disorders effectively and safely.
research Efficacy and safety of tofacitinib in patients with total and universal alopecia- A retrospective evaluation of 69 patients
Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.
research Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.
research Baricitinib Achieved Complete/Near Complete Scalp Coverage in SALT Score ≤20 Responders: 52-Week Findings From BRAVE-AA Trials
Baricitinib significantly regrows hair in severe alopecia areata patients.
research Sex hormones and related compounds, including hormonal contraceptives
Exposure to certain sex hormones can increase health risks, while some hormone therapies may offer benefits for specific conditions.
research 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
research Efficacy and Safety of Ritlecitinib in Alopecia Areata: A Systematic Review and Meta-Analysis (Preprint)
Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.
research Hydroxysteroid Dehydrogenase (17β -HSD3, 17β-HSD5, and 3α-HSD3) Inhibitors:Extragonadal Regulation of Intracellular Sex Steroid Hormone Levels
Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.
research Cancer vaccine strategies and studies of human thioredoxin reductase splice variants
Vaccines and targeting TrxR variants can help prevent cancer and reduce metastasis.
research Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy
Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.
research Rapid hair depigmentation in patient treated with pazopanib
Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.
research Differential expression of steroid 5α-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer
SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.
research Vitamin E TPGS based transferosomes augmented TAT as a promising delivery system for improved transdermal delivery of raloxifene
The new delivery system improved raloxifene's skin absorption and effectiveness against cancer cells.